Trial of Deferiprone in Parkinson’s Disease

Iron deposition in the substantia nigra has been implicated in Parkinson’s disease. Chelation with deferiprone reduced brain iron content but led to worse scores on scales of the movement disorder at 36 weeks.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 387; číslo 22; s. 2045 - 2055
Hlavní autoři:	Devos, David, Labreuche, Julien, Rascol, Olivier, Corvol, Jean-Christophe, Duhamel, Alain, Guyon Delannoy, Pauline, Poewe, Werner, Compta, Yaroslau, Pavese, Nicola, Růžička, Evžen, Dušek, Petr, Post, Bart, Bloem, Bastiaan R., Berg, Daniela, Maetzler, Walter, Otto, Markus, Habert, Marie-Odile, Lehericy, Stéphane, Ferreira, Joaquim, Dodel, Richard, Tranchant, Christine, Eusebio, Alexandre, Thobois, Stéphane, Marques, Ana-Raquel, Meissner, Wassilios G., Ory-Magne, Fabienne, Walter, Uwe, de Bie, Rob M.A., Gago, Miguel, Vilas, Dolores, Kulisevsky, Jaime, Januario, Cristina, Coelho, Miguel V.S., Behnke, Stefanie, Worth, Paul, Seppi, Klaus, Ouk, Thavarak, Potey, Camille, Leclercq, Céline, Viard, Romain, Kuchcinski, Gregory, Lopes, Renaud, Pruvo, Jean-Pierre, Pigny, Pascal, Garçon, Guillaume, Simonin, Ophélie, Carpentier, Jessica, Rolland, Anne-Sophie, Nyholm, Dag, Scherfler, Christoph, Mangin, Jean-François, Chupin, Marie, Bordet, Régis, Dexter, David T., Fradette, Caroline, Spino, Michael, Tricta, Fernando, Ayton, Scott, Bush, Ashley I., Devedjian, Jean-Christophe, Duce, James A., Cabantchik, Ioav, Defebvre, Luc, Deplanque, Dominique, Moreau, Caroline
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 01.12.2022
Edice:	New England Journal of Medicine
Témata:	Administration, Oral Aging Aging General Antiparkinson Agents - administration & dosage Antiparkinson Agents - adverse effects Antiparkinson Agents - pharmacology Antiparkinson Agents - therapeutic use Basal ganglia Body weight Brain - diagnostic imaging Brain Chemistry Central nervous system diseases Clinical trials Cognitive ability Deferiprone - administration & dosage Deferiprone - adverse effects Deferiprone - pharmacology Deferiprone - therapeutic use Disease Progression Dopamine Dopamine Agents - administration & dosage Dopamine Agents - adverse effects Dopamine Agents - pharmacology Dopamine Agents - therapeutic use Dopamine receptors Double-Blind Method Double-blind studies Genetics Geriatrics Hematology Humans Iron Iron - analysis Iron - metabolism Iron Chelating Agents - administration & dosage Iron Chelating Agents - adverse effects Iron Chelating Agents - pharmacology Iron Chelating Agents - therapeutic use Levodopa Levodopa - therapeutic use Life Sciences Magnetic resonance imaging Metabolism Movement disorders Neurodegenerative diseases Neuroimaging Neurology Neuroscience Neurosurgery Neutropenia Neutropenia - chemically induced Oncology Oncology General Parkinson Disease Parkinson Disease - drug therapy Parkinson Disease - metabolism Parkinson Disease - physiopathology Parkinson's disease Placebos Quality of life Substantia nigra Substantia Nigra - chemistry Substantia Nigra - diagnostic imaging Substantia Nigra - drug effects Substantia Nigra - metabolism France Parkinson Disease Neuroscience Geriatrics/Aging Hematology/Oncology
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Iron deposition in the substantia nigra has been implicated in Parkinson’s disease. Chelation with deferiprone reduced brain iron content but led to worse scores on scales of the movement disorder at 36 weeks.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2209254